Efficient in vitro and in vivo RNA editing via recruitment of endogenous ADARs using circular guide RNAs

Dhruva Katrekar1, James Yen1, Yichen Xiang1, Anushka Saha1, Dario Meluzzi2, Yiannis Savva3 and Prashant Mali1✉

Recruiting endogenous adenosine deaminases using exogenous guide RNAs to edit cellular RNAs is a promising therapeutic strategy, but editing efficiency and durability remain low using current guide RNA designs. In this study, we engineered circular ADAR-recruiting guide RNAs (cadRNAs) to enable more efficient programmable adenosine-to-inosine RNA editing without requiring co-delivery of any other proteins. Using these cadRNAs, we observed robust and durable RNA editing across multiple sites and cell lines, in both untranslated and coding regions of RNAs, and high transcriptome-wide specificity. Additionally, we increased transcript-level specificity for the target adenosine by incorporating interspersed loops in the antisense domains, reducing bystander editing. In vivo delivery of cadRNAs via adeno-associated viruses enabled 53% RNA editing of the mPCSK9 transcript in C57BL/6J mice livers and 12% UAG-to-UGG RNA correction of the amber nonsense mutation in the IDUA-W392X mouse model of mucopolysaccharidosis type I-Hurler syndrome. cadRNAs enable efficient programmable RNA editing in vivo with diverse protein modulation and gene therapeutic applications.

adenosine-to-inosine (A-to-I) RNA editing is a common post-transcriptional modification catalyzed by adenosine deaminases acting on RNA (ADAR) enzymes1–7. ADARs edit double-stranded RNA (dsRNA) predominantly in non-coding regions such as Alu repetitive elements in a promiscuous fashion while also editing a handful of sites in coding regions with high specificity8–12. The structural similarity between inosine and guanosine results in the translation and splicing machinery recognizing the edited base as guanosine, thereby making ADARs attractive tools for recoding protein sequences13. To this end, several studies recently repurposed the ADAR system for programmable RNA editing both in vitro14–22 and in vivo20,23 by engineering recruitment of ADARs to a target RNA sequence using ADAR-recruiting guide RNAs (adRNAs). Although ADARs and, in particular, ADAR1, are widely expressed throughout the body, most of these studies relied on exogenously delivered ADAR enzymes and their variants to achieve robust RNA editing efficiencies. However, as ADAR–dsRNA interactions primarily rely on structure dependency rather than sequence dependency, a major limitation of relying on enzyme overexpression is the propensity to introduce a plethora of off-target A-to-I edits across the transcriptome14,20,24,25. Additionally, as ADARs are native to and, thus, not orthogonal to most mammalian systems, their overexpression can result in altered protein interactions that might affect cellular physiology. Furthermore, as this approach relies on two components, a guide RNA and the ADAR protein, it can limit delivery modalities, in particular for in vivo applications.

A solution to this is to engineer adRNAs to enable recruitment of endogenous ADARs. Toward this, we recently showed that it is possible to recruit endogenous ADARs using simple long antisense RNAs of length greater than 60 bp20. This strategy is exciting because, akin to short-hairpin RNAs (shRNAs) and antisense oligonucleotides (ASOs), which efficaciously recruit endogenous cellular machinery such as Argonaute26 and RNase H27,28 to enable targeted RNA knockdown, just delivery of guide RNAs alone can now enable programmable A-to-I RNA editing without requiring co-delivery of any exogenous proteins. However, the efficiency of RNA editing via this approach is typically lower than seen with chemically synthesized ASOs. Additionally, these enable highly robust RNA editing in both untranslated and coding regions of mRNAs and across multiple RNA targets and cell lines. Notably, using cadRNAs, we also show, to our knowledge for the first time, robust RNA editing via endogenous ADAR recruitment, including in the IDUA-W392X mouse model of mucopolysaccharidosis type I-Hurler syndrome.

Results

Using our long antisense guide RNA design20 that can recruit endogenous ADARs as a base format, we explored two guide RNA engineering strategies to enhance RNA editing efficiencies (Fig. 1a): one, we coupled recruiting domains that are derived from native RNA sites known to be heavily edited by ADARs; and two, we coupled domains that stabilize and confer increased half-life of the guide RNAs (Supplementary Table 1).

1Department of Bioengineering, University of California, San Diego, San Diego, CA, USA. 2Department of Medicine, University of California, San Diego, San Diego, CA, USA. 3Shape Therapeutics, Seattle, WA, USA. ✉e-mail: pmali@ucsd.edu
Toward the former, we evaluated recruiting domains from the naturally occurring ADAR2 substrate GluR2 pre-mRNA\(^{16,17}\) and Alu elements, which are known substrates for ADAR1 (ref. \(^29\)). The Alu adRNAs were created by positioning the antisense domain within the Alu consensus sequence and eliminating any poly-U stretches. We screened these modified guide RNAs by assaying

### a

| Hours after transfection | % edited mRNA (RAB7A) |
|--------------------------|-----------------------|
| 48 h                     | -                     |
| 96 h                     | -                     |

### b

% edited mRNA (RAB7A)—48 h vs. 96 h

### c

Confirmation of circularization

### d

RNA editing via endogenous ADAR1
Articles NATURE BIOTECHNOLOGY

Fig. 1 | Engineering cadRNAs. a. Comparison of the RNA editing efficiencies in the 3' UTR of the RAB7A transcript via various adRNA designs. Values represent mean ± s.e.m. (n = 3; with respect to the linear.100.50, left-to-right, P = 0.7289, P = 0.0226, P = 0.0019, P = 0.0055, P = 0.0027 and P = 0.0006; unpaired t-test, two tailed). In the schematics, the pink strand represents the antisense domain of the adRNA, whereas the target mRNA is in blue. The bulge indicates the A-C mismatch between the target mRNA and adRNA. The adRNAs are labeled using the following convention: (domain name). (antisense length).(position of A-C mismatch from 5' end of the antisense). b. RNA editing efficiencies achieved 48 h and 96 h after transfection of various adRNA designs. Values represent mean ± s.e.m. (n = 3; left-to-right, P = 0.0019, P = 0.0027, P = 0.0006, P = 0.8488, P = 0.0014 and P = 0.0077; unpaired t-test, two tailed). The 48-h panel data are reproduced from a, c. RT–PCR-based confirmation of adRNA circularization in cells. d. The ability of adRNAs to effect RNA editing of the cluc transcript was assessed in the presence of an siRNA targeting ADAR1. Values represent mean ± s.e.m. (n = 3; left-to-right, P = 0.0002, P = 0.0216 and P = 0.0001; unpaired t-test, two tailed). All experiments were carried out in HEK293FT cells. NS, not significant.

Fig. 2 | Transcriptome-wide and target transcript-level specificity profiles of cadRNAs. a. Left, 2D histograms comparing the transcriptome-wide A-to-G editing yields observed with a cadRNA construct (y axis) with the yields observed with the control sample (x axis). Each histogram represents the same set of reference sites, where read coverage was at least 10, and at least one putative editing event was detected in at least one sample. N_{up} is the number of sites with significant changes in editing yield. Points corresponding to such sites are shown with red crosses. The on-target editing values obtained via Sanger sequencing for the samples are HEK293FT: 0%; circular.100.50: 40.47%; and circular.200.100: 43.54%. Right, a comparison of the number of off-targets induced by delivery of circular adRNAs, linear adRNAs and linear adRNAs with co-delivered ADAR2 (ref. 23). b. Engineered cadRNA designs for reducing bystander editing. Design 1 (cadRNA): unmodified circular.200.100 antisense. Design 2 (cadRNA:bulges): antisense bulges created by positioning guanosines opposite bystander-edited adenosines. Design 3 (cadRNA:loops): loops of size 8 bp created at positions −5 and +30 relative to the target adenosine. Design 4 (cadRNA:loops.interspersed): loops of size 8 bp created at positions −5 and +30 relative to the target adenosine and additional 8-bp loops added at 15-bp intervals all along the antisense strand. Plots depicting the location and extent of all substitutions in the 200-bp dsRNA stretch (n = 1 representative plot shown for each construct, analyzed by CRISPRESSo2 (ref. 23)). c. Plots depict percentage of on-target edited or unedited reads with and without further A-to-G hyperedits in the 200-bp dsRNA stretch formed between the cadRNA and target RNA as observed with the various designs. Substitutions other than A-to-G were not considered for this analysis. Values represent mean ± s.e.m. as quantified by next-generation sequencing (n = 3). d. Heat maps of percent editing within a 60-bp window around the target adenosine in the GAPDH and RAB7A transcripts. The positions of adenosines relative to the target adenosine (O) are listed to the left of the heat map. Values represent mean (n = 2). All experiments were carried out in HEK293FT cells.

ing at an adenosine in the 3' untranslated region (UTR) of the RAB7A transcript in HEK293FT cells. Consistent with our previous observations, the GluR2 domain coupled to a short antisense of length 20 bp with the A-C mismatch located 6 bp from the 5' end of the antisense domain (GluR2.20.6) was unable to recruit endogenous ADARs, resulting in no detectable RNA editing, whereas, as we previously showed, long antisense RNAs with a centrally located A-C mismatch (linear.100.50) resulted in modest ~10% RNA editing. Coupling the GluR2 domains to the long antisense version (GluR2.100.50) did not further enhance RNA editing yields, but we observed that the addition of Alu domains (Alu.100.50) marginally enhanced the efficiency of RNA editing (1.5-fold). Although significant, these designs had only a modest improvement over the base format of simple long antisense guide RNAs.

We thus focused next on evaluating the effect of persistence of guide RNAs, as this, in turn, could also affect target RNA search as well as their net target residence times. In particular, genetically encoded adRNAs are typically expressed via the polymerase III promoter, and, thus, transcribed guides lack a 5' cap and a 3' poly-A tail and, correspondingly, have very short half-lives. To improve guide RNA persistence, we evaluated (1) increasing the length of the guide RNAs (linear.200.100); (2) coupling a U6+27 cassette (U6+27.100.50), which has been shown to improve stability of small interfering RNA (siRNA)30; and (3) engineering circularized versions (circular.100.50 and circular.200.100), as these would be intrinsically resistant to cellular exonucleases. Specifically, leveraging an elegant methodology recently developed by Litke et al., we engineered cadRNAs by flanking the linear adRNAs by twister ribozymes, which, upon autocatalytic cleavage, leave termini that are ligated by the ubiquitous endogenous RNA ligase RtcB to yield circularized guide RNAs. Comparing the three different guide designs, we observed that both the increase of adRNA length and the addition of U6+27 to the long antisense adRNA led to a 1.5-fold and two-fold respective improvement in editing of the RAB7A transcript over the linear.100.50 designs (Fig. 1a). Notably, using circular adRNA with antisense lengths of 100 bp and 200 bp (that is, circular.100.50 and circular.200.100) resulted in an even more robust 3.5-fold improvement in efficiency over the linear.100.50 designs and a two-fold improvement over the Alu.100.50 and U6+27.100.50 designs (Fig. 1a). Excitingly, we observed persistence of significant levels in RNA editing at both 48 h and 96 h after transfection via these, whereas editing via linear guide RNAs was almost undetectable by the 96-h time point (Fig. 1b). We confirmed that U6-transcribed ribozyme-flanked adRNAs were covalently circularized in cells, forming cadRNAs, which were detected via RT–PCR by designing outward-facing primers that selectively amplified only the circularized structure (Fig. 1c).

To confirm that circularization was indeed essential for boosting RNA editing (Fig. 1a,b), we flanked the antisense sequence with catalytically inactive mutants of the twister ribozymes (ribozyme.mutant.200.100). This led to a significant decrease in RNA editing at both 48 h and 96 h after transfections, with observed RNA editing levels similar to the linear versions (Extended Data Fig. 1a). qPCR analysis confirmed the absence of circular adRNAs in cells transfected with ribozyme.mutant.200.100 (Extended Data Fig. 1b). Additionally, in cells transfected with circular.200.100 plasmid, a significant fraction of the U6-transcribed adRNA was present in the circular form (Extended Data Fig. 1b). To further ascertain that the long half-lives of the cadRNAs were responsible for persistent RNA editing observed, we treated cells transfected with circular.200.100 and ribozyme.mutant.200.100 plasmids with actinomycin D, a transcription inhibitor. Within 6 h after treatment, we observed a significant reduction in the amounts of the ribozyme.mutant.200.100 adRNA, whereas the levels of circular.200.100 adRNA remained constant (Extended Data Fig. 1c). We also evaluated the intracellular localization of cadRNAs and detected them at high levels both in the nucleus and in the cytoplasm (Extended Data Fig. 1d).

Notably, we confirmed that RNA editing via the circular guide RNAs, similarly to the linear guide RNAs, was mediated by endogenous ADAR1 recruitment. Toward this, we performed a luciferase-based reporter assay, where we assayed the guide RNAs for their ability to repair a premature stop codon (UAG).
in the *Cypridina* luciferase (cluc) transcript\(^1\) in the presence of scrambled and ADAR1-specific siRNAs. We observed a significant drop in luciferase activity in the presence of ADAR1 siRNA, confirming that RNA editing via long antisense adRNAs and circular adRNAs was dependent upon endogenous ADAR1 levels (Fig. 1d).

---

**a** Transcriptome wide specificity profiles

**b** Curbing bystander editing: GAPDH

**c**

**d** GAPDH (CDS) and RAB7A (3' UTR)
We next sought to evaluate the specificity profile of cadRNAs at both the transcriptome-wide and target transcript levels. Toward the former, a circular.100.100 sample and a circular.200.100 sample, along with an untransfected HEK293FT sample, were analyzed by deep RNA sequencing (RNA-seq). Notably, in contrast to enzyme overexpression where we routinely observed $10^3$–$10^4$ transcriptome-wide off-targets\(^2\), we noted 2–3 orders of magnitude lower off-target editing via the cadRNAs and at levels similar to the transcriptome-wide off-targets\(^2\). Associated changes in expression levels of target transcripts as compared to levels seen in untransfected controls are also shown, 48 h after transfections ($P = 0.2599, P = 0.0135, P = 0.1982, P = 0.7871, P = 0.0144, P = 0.2674, P = 0.1168, P = 0.7852$ and $P = 0.5145$; unpaired t-test, two-tailed).

In vitro transcribed RNA delivery

- We engineered 8-bp loops positioned both 5 bp upstream and 30 bp downstream of the target adenosine (cadRNA.loops). This design led to a significant reduction in bystander editing within the 36-bp region between the bulges, with the on-target editing being double that achieved by simply placing opposing G mismatches (Fig. 2b–d). However, we still observed significant bystander editing in the adenosines flanking the 36-bp region. We hypothesized that it might be possible to eliminate these via positioning of 8-bp loops all along the antisense domain at intervals of 15 bp flanking the 36-bp central region that carries the target adenosine (cadRNA.loops.interspersed). Indeed, this design substantially reduced bystander editing in the 200-bp dsRNA stretch formed between the target mRNA and the antisense domain while maintaining on-target editing levels similar to the unmodified circular.200.100 construct (Fig. 2b–d and Extended Data Fig. 2). Taken together, a combination of appropriately positioned 8–12-bp loops to create breaks within the long stretch of dsRNA, along with certain A-specific bulges, can thus be used to eliminate bystander editing in a target-specific manner (Fig. 2b–d and Extended Data Fig. 2).

Next, we confirmed the robustness and generalizability of the cadRNA format by its ability to successfully edit adenosines in the 3′ UTR and coding sequence of seven additional...
Given the vastly improved efficiency and durability of RNA editing via cadRNAs, we next wondered if these could enable in vivo RNA editing. Because no co-delivery of proteins is required, successful demonstration here could enable a powerful gene therapy approach. Additionally, for the cadRNAs, one could leverage the already established delivery modalities and accruing knowledge from the field of shRNAs and ASOs that similarly only require delivery of nucleic acids to target tissues. To explore this, we first targeted an adenosine in the 3′ UTR of the mPCSK9 transcript via AAV8-mediated delivery of adRNAs to the mouse liver. We systematically compared RNA editing yields via linear.U6+2.700.100, one copy of circular.200.100 and two copies of circular.200.100 guide RNAs (Fig. 4a). Two weeks after injections, we harvested mice livers and did not detect any editing in the PBS-injected mice or in mice injected with AAV8-mCherry. Notably, in the mice injected with AAV8-linear.U6+2.700.100 guide RNAs, we also did not measure detectable RNA editing (Fig. 4b). Excitingly, we observed highly efficient 11% and 38% on-target editing via the AAV8-delivered single-copy (1x) and two-copy (2x) circular.200.100 guide RNAs, respectively. Additionally, editing via AAV8-2x.circular.200.100 was persistent, with mPCSK9 editing levels of 53% observed 8 weeks after injections. We confirmed robust expression of the cadRNAs via qPCR, and we noted that the addition of a second copy of the circular.200.100 led to a three-fold increase in expression levels, together suggesting that persistent and robust guide RNA expression was key to enabling efficient in vivo RNA editing (Fig. 4c). Notably, we also confirmed that cadRNAs delivered via AAVs did not alter the expression levels of the mPCSK9 transcript in mice livers (Fig. 4d).

To evaluate the specificity profiles of the cadRNAs in vivo and also systematically study their effects on gene expression, we carried out RNA-seq on four C57BL6/J littermates, two injected with AAV8-mCherry and two injected with AAV8-2x.circular.200.100, 2 weeks after injections. We observed precise transcript-specific editing of the PCSK9 mRNA in these mice (Extended Data Fig. 4). Furthermore, we carried out qPCR on several interferon-stimulated genes, especially those involved in sensing dsRNA, such as RIG-I, MDA5, OAS1A, OSL, OASL2 and PKR. In the short-term experiments, we did not observe significant changes in the levels of many of these genes, but we observed that there was an increase in the levels of MDA5 and PKR in the mice injected with AAV8-2x.circular.200.100 as compared to the AAV8-mCherry control group. However, in the long-term experiments, we did not observe significant changes in the levels of any of these genes when compared to the AAV control group (Extended Data Fig. 5a). Additionally, we also confirmed that presence of the cadRNAs did not significantly alter the expression of ADAR1-p110, ADAR1-p150 and ADAR2 as compared to the AAV control group (Extended Data Fig. 5b). Differential expression analyses also confirmed no alterations in gene groups involved in sensing foreign RNA (Extended Data Fig. 5c).

Building on these results, we next targeted a mouse model of Hurler syndrome. Hurler syndrome is a form of mucopolysaccharidosis type 1, a rare genetic disorder that results in the buildup of large sugar molecules called glycosaminoglycans (GAGs) in lysosomes. This occurs due to a lack of the enzyme α-L-iduronidase, which is encoded by the IDUA gene. W402X is a commonly occurring mutation in the IDUA gene in patients with Hurler syndrome, and there exists a corresponding mouse model bearing the IDUA-W392X mutation (Fig. 3e). With a goal to repair the IDUA-W392X premature stop codon, we packaged two copies of IDUA.circular.200.100 adRNA into AAV8 and injected these into IDUA-W392X mice systemically. As a control, we included an AAV8-2x.scrambled.circular.200.100. Two weeks after injection, we harvested mice livers and observed robust 7–17% correction of the premature stop codon in the mice injected with the AAV8-2x.IDUA.circular.200.100 adRNA (Fig. 3f). We confirmed that expression of the circular.200.100 adRNA did not alter the expression levels of the IDUA transcript (Fig. 3g). We also measured GAG levels in these mice and observed about 33% less GAG accumulation in the treated animals over the 2-week period as compared to the scrambled control mice, indicating successful partial restoration of α-L-iduronidase activity (Fig. 3h).

**Discussion**

Use of endogenous ADARs for correction of G-to-A point mutations and premature stop codons has considerable therapeutic potential. However, the relatively short half-life of the guide RNAs limits efficacy. In this study, we engineered cadRNAs for recruitment of endogenous ADARs that vastly improve the efficiency and durability of programmable RNA editing. This method is highly specific at the transcriptome level, and engineering of interspersed loops in the antisense domain also enabled high specificity at the transcript level, with significantly reduced bystander adenosine editing. Via AAV-delivered cadRNAs, we also showed, to our knowledge for the first time, robust, persistent and highly transcript-specific in vivo RNA editing via endogenous ADAR recruitment, including in the IDUA-W392X mouse model of MPS I-H syndrome. Although cadRNAs provide an exciting format for RNA editing, several areas merit further investigation. (1) While the circular.200.100 adRNAs provide a general framework to achieve robust and persistent RNA editing, we did observe variations in editing yields across targets.
Further target-specific optimizations, while considering local sequence and structural contexts (such as pre-straining or secondary structure modulation of the cadRNA, for instance, if the antisense domain is part of a stable duplex and is unavailable to bind its target), will be important to further improve cadRNA editing yields. (2) Coupling additional ADAR recruitment domains onto the cadRNA might also further help boost editing yields. (3) For the IVT formats, we anticipate that introduction of modified RNA
bases such as pseudouridines or completion of circularization before delivery might be critical for enhancing cadRNA efficacy. (4) Also, as noted both in this and our previous work, although most targets maintained expression levels, for some targets clear RNA interference (RNAi) effects are observed via both long antisense adRNAs and cadRNAs, and, correspondingly, modifying those guide designs will be critical to enable efficacious editing. (5) Additionally, the effect on protein translation upon binding of the long antisense domains to the target mRNA needs further assessment. (6) Finally, on the in vivo studies front, although the 2-week-long experiments analyzed by RNA-seq did not reveal enrichment of any gene groups involved in sensitive foreign RNA, the effects of cadRNA accumulation will need to be carefully monitored over longer periods of time.

Taken together, as cadRNAs do not require the need for co-delivery of any effector proteins and, as a targeting moiety, also have enhanced persistence in cells, they have the potential for broad utility in programmable RNA-editing-mediated transient protein modulation as well as correction of G-to-A point mutations and premature stop codons for therapeutic applications. Moving beyond, we anticipate that circularization of guide RNAs might also have utility in other transcriptome and genome engineering modalities, such as RNAi, ASOs and guide RNAs in CRISPR–Cas.

Online content
Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41587-021-01171-4.

Received: 15 January 2021; Accepted: 24 November 2021; Published online: 10 February 2022

References
1. Melcher, T. et al. A mammalian RNA editing enzyme. Nature 379, 460–464 (1996).
2. Basa, B. L. & Weintraub, H. An unwinding activity that covalently modifies its double-stranded RNA substrate. Cell 55, 1089–1098 (1988).
3. Basa, B. L. & Weintraub, H. A developmentally regulated activity that unwinds RNA duplexes. Cell 48, 667–613 (1987).
4. Mannion, N. M. et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 9, 1482–1494 (2019).
5. Tomasselli, S. et al. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol. 16, 5 (2015).
6. Schoft, V. K., Schopoff, S. & Jantsch, M. F. Regulation of glutamate receptor B pre-mRNA splicing by RNA editing. Nucleic Acids Res. 35, 3723–3732 (2007).
7. Wagner, R. W., Smith, J. E., Cooperman, B. S. & Nishikura, K. A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. Proc. Natl Acad. Sci. USA 86, 2647–2651 (1989).
8. Nishikura, K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat. Rev. Mol. Cell Biol. 17, 83–96 (2016).
9. Peng, Z. et al. Comprehensive analysis of RNA-seq data reveals extensive RNA editing in a human transcriptome. Nat. Biotechnol. 30, 253–260 (2012).
10. Egginton, J. M., Greene, T. & Bass, B. L. Predicting sites of ADAR editing in double-stranded RNA. Nat. Commun. 2, 219 (2011).
11. Tan, M. H. et al. Dynamic landscape and regulation of RNA editing in mammals. Nature 550, 239–254 (2017).
12. Levanon, E. Y. et al. Systematic identification of abundant A-to-I editing sites in the human transcriptome. Nat. Biotechnol. 22, 1001–1005 (2004).
13. Wood, T. M., Chase, J. M. & Stinchcomb, D. T. Toward the therapeutic editing of mutated RNA sequences. Biochemistry 92, 8298–8302 (1995).
14. Staffor, T. & Schneider, M. F. A RNA-deaminase conjugate selectively repairs point mutations. Angew. Chem. Int. Ed. 51, 11166–11169 (2012).
15. Montiel-Gonzalez, M. F., Valleccillo-Viejo, I., Yudowksi, G. A. & Rosenthal, J. J. C. Correction of mutations within the cystic fibrosis transmembrane conductance regulator by site-directed RNA editing. Proc. Natl Acad. Sci. USA 110, 18285–18290 (2013).
16. Wetogen, J., Reautschning, P., Geisler, S., Kahlhe, P. J. & Staffor, T. Harnessing human ADAR2 for RNA repair—recoding a PINK1 mutation rescues mitophagy. Nucleic Acids Res. 45, 2797–2808 (2017).
17. Fukuda, M. et al. Construction of a guide-RNA for site-directed RNA mutagenesis utilising intracellular A-to-I RNA editing. Sci. Rep. 7, 41478 (2017).
18. Cox, D. B. T. et al. RNA editing with CRISPR-Cas13. Science 358, 1019–1027 (2017).
19. Merkle, T. et al. Precise RNA editing by recruiting endogenous ADARs with antisense oligonucleotides. Nat. Biotechnol. 37, 133–138 (2019).
20. Katrek, D. et al. In vivo RNA editing of point mutations via RNA-guided adenosine deaminases. Nat. Methods 16, 239–242 (2019).
21. Qu, L. et al. Programmable RNA editing by recruiting endogenous ADAR using engineered RNAs. Nat. Biotechnol. 37, 1039–1069 (2019).
22. Monteleone, L. R. et al. A bump-hole approach for directed RNA editing. Cell Chem. Biol. 26, 269–277 (2019).
23. Sinnen, J. R. et al. In vivo repair of a protein underlying a neurological disorder by programmable RNA editing. Cell Rep. 32, 107678 (2020).
24. Valleccillo-Viejo, I. C., Liscovich-Brauer, N., Montiel-Gonzalez, M. F., Eisenberg, E. & Rosenthal, J. J. C. Abundant off-target edits from site-directed RNA editing can be reduced by nuclear localization of the editing enzyme. RNA Biol. 15, 104–114 (2018).
25. Vogel, P. et al. Efficient and precise editing of endogenous transcripts with SNAP-tagged ADARs. Nat. Methods 15, 535–538 (2018).
26. Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391, 806–811 (1998).
27. Zamecnik, P. C. & Stephenson, M. L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl Acad. Sci. USA 73, 280–284 (1978).
28. Daus, N. & Stein, C. A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347–355 (2002).
29. Chung, H. et al. Human ADAR1 prevents endogenous RNA from triggering translational shutdown. Cell 172, 811–824 (2018).
30. Paul, C. P., Good, P. D., Winer, I. & Engikel, D. R. Effective expression of small interfering RNA in human cells. Nat. Biotechnol. 20, 505–508 (2002).
31. Litke, J. L. & Jaffrey, S. R. Highly efficient expression of circular RNA aptamers in cells using autocatalytic transcripts. Nat. Biotechnol. 37, 667–675 (2019).
32. Heep, M., Mach, P., Reautschning, P., Wetogen, J. & Staffor, T. Applying human ADAR1p110 and ADAR1p150 for site-directed RNA editing—G/C substitution stabilizes guideRNAs against editing. Genes 8, 34 (2017).
33. Lehmann, K. A. & Bass, B. L. The importance of internal loops within RNA substrates of ADAR1. J. Mol. Biol. 291, 1–13 (1999).
34. Chen, Y. G. et al. Sensing self and foreign circular RNAs by intron identity. Mol. Cell 67, 228–238 (2017).
35. Wang, D. et al. Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation. Mol. Genet. Metab. 99, 62–71 (2010).
36. Clement, K. et al. CRISPResso2 provides accurate and rapid genome editing sequence analysis. Nat. Biotechnol. 37, 224–226 (2019).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. © The Author(s), under exclusive licence to Springer Nature America, Inc. 2022
Methods

**Transfections.** Unless otherwise stated, experiments were carried out in HEK293FT cells (Thermo Fisher Scientific, R70007), which were grown in DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic (Thermo Fisher Scientific) in an incubator at 37 °C and 5% CO2 atmosphere. HEK293FT cells were seeded in 24-well plates and transfected using 1,000 ng of adRNA plasmid or 48 pmol of IVT RNA and 2 μl of Lipofectamine 2000 (Thermo Fisher Scientific). Cells were transfected at 25–30% confluence. Plasmid transfection experiments were harvested 48 h after transfections, whereas IVT RNA experiments were harvested 24 h after transfections. For 96-hour-long experiments, cells were passaged at a 1:4 ratio, 48 h after transfections. Cells after plasmid electroporation were harvested at 48 h, whereas IVT RNA experiments were harvested 24 h after electroporation.

**Electroporation.** K362 cells (American Type Culture Collection (ATCC), CCL-243) were grown in RPMI supplemented with 10% FBS and 1% antibiotic-antimycotic (Thermo Fisher Scientific) in an incubator at 37 °C and 5% CO2 atmosphere. HEK293FT cells were harvested using 1 ml of PBS with a GAG assay.

**Actinomycin D (5 μmol/L) was added to the 96-well plate in the dark.** The luminescence was read with 0.5 ml of Vargulin substrate (Thermo Fisher Scientific) at 37 °C and 5% CO2 atmosphere. All in vitro luciferase experiments were carried out in HEK293FT cells seeded in 96-well plates, at 25–30% confluency, using 200 ng of total plasmid and 0.4 μl of Lipofectamine 2000 (Thermo Fisher Scientific). Specifically, every well received 100 ng each of the CICL-W85X (TAG) reporter and the adRNA plasmids. At the same time, every well also received 25 pmol of siRNA. Forty-eight hours after transfection, 20 μl of supernatant from cells was added to a Costar black 96-well plate (Corning). For the readout, 50 μl of Cypidine Glow Assay Buffer was mixed with 0.5 μl of vargulin substrate (Thermo Fisher Scientific) and added to the 96-well plate in the dark. The luminescence was read within 10 min on SpectraMax i3x or iD3 plate readers (Molecular Devices) (Scientific) and added to the 96-well plate. In total, 200,000 cells were electroporated with 1,000 ng of adRNA plasmid or 48 pmol of IVT RNA using the Amaxa SF cell line 4D-Nucleofector X Kit (Lonza) as per the manufacturer's instructions.

**IVT.** Sense RNA fragments and circular adRNA were made by IVT using the HiScribe T7 Quick High Yield RNA Synthesis Kit (NEB) as per the manufacturer's protocol. DNA templates for the IVT reaction carried the T7 promoter sequence at the 5′ end and were created by PCR amplification of the desired sequence from plasmids or cDNA. PCR products were purified using a PCR Purification Kit (Qiagen) and then used for IVT.

**Luciferase assay.** HEK293FT cells were grown in DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic (Thermo Fisher Scientific) in an incubator at 37 °C and 5% CO2 atmosphere. All in vitro luciferase experiments were carried out in HEK293FT cells seeded in 96-well plates, at 25–30% confluency, using 200 ng of total plasmid and 0.4 μl of Lipofectamine 2000 (Thermo Fisher Scientific). Specifically, every well received 100 ng each of the CICL-W85X (TAG) reporter and the adRNA plasmids. At the same time, every well also received 25 pmol of siRNA. Forty-eight hours after transfection, 20 μl of supernatant from cells was added to a Costar black 96-well plate (Corning). For the readout, 50 μl of Cypidine Glow Assay Buffer was mixed with 0.5 μl of vargulin substrate (Thermo Fisher Scientific) and added to the 96-well plate in the dark. The luminescence was read within 10 min on SpectraMax i3x or iD3 plate readers (Molecular Devices) (Scientific) and added to the 96-well plate. In total, 200,000 cells were electroporated with 1,000 ng of adRNA plasmid or 48 pmol of IVT RNA using the Amaxa SF cell line 4D-Nucleofector X Kit (Lonza) as per the manufacturer's instructions.

**Actinomycin D treatment.** Twenty-four hours after transfections, media with actinomycin D (5 μg/ml) was added to the indicated duration of time.

**Production of AAV vectors.** AA8V particles were produced using HEK293FT cells via the triple-transfection method and purified via an iodixanol gradient.

**Confluency at transfection was about 50%.** Two hours before transfection, cell medium was exchanged with DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic (Gibco). All viruses were produced in 5 × 15 cm plates, at 90% confluence, at 37 °C and 5% CO2 atmosphere. HEK293FT cells were harvested using 1 ml of PBS (pH 7.2) supplemented with 50 mM β-mercaptoethanol (Thermo Fisher Scientific) and then used for IVT.

**IVT.** Sense RNA fragments and circular adRNA were made by IVT using the HiScribe T7 Quick High Yield RNA Synthesis Kit (NEB) as per the manufacturer's protocol. DNA templates for the IVT reaction carried the T7 promoter sequence at the 5′ end and were created by PCR amplification of the desired sequence from plasmids or cDNA. PCR products were purified using a PCR Purification Kit (Qiagen) and then used for IVT.

**Luciferase assay.** HEK293FT cells were grown in DMEM supplemented with 10% FBS and 1% antibiotic-antimycotic (Thermo Fisher Scientific) in an incubator at 37 °C and 5% CO2 atmosphere. All in vitro luciferase experiments were carried out in HEK293FT cells seeded in 96-well plates, at 25–30% confluency, using 200 ng of total plasmid and 0.4 μl of Lipofectamine 2000 (Thermo Fisher Scientific). Specifically, every well received 100 ng each of the CICL-W85X (TAG) reporter and the adRNA plasmids. At the same time, every well also received 25 pmol of siRNA. Forty-eight hours after transfection, 20 μl of supernatant from cells was added to a Costar black 96-well plate (Corning). For the readout, 50 μl of Cypidine Glow Assay Buffer was mixed with 0.5 μl of vargulin substrate (Thermo Fisher Scientific) and added to the 96-well plate in the dark. The luminescence was read within 10 min on SpectraMax i3x or iD3 plate readers (Molecular Devices) (Scientific) and added to the 96-well plate. In total, 200,000 cells were electroporated with 1,000 ng of adRNA plasmid or 48 pmol of IVT RNA using the Amaxa SF cell line 4D-Nucleofector X Kit (Lonza) as per the manufacturer's instructions.
Quantification of changes in RNA editing. To quantify significant changes in RNA editing, the BAM files containing reads aligned to the reference genome were processed as follows. Reads marked as duplicates were ignored. To minimize the bias of library size on statistical comparisons between different samples, the remaining reads from each sample were downsampled, using SAMTools view with option -s, to the smallest number of such reads available for any sample. The downsampling fraction used for each sample was calculated by dividing the smallest number of uniquely aligned reads among all samples by the number of uniquely aligned reads available for the sample being downsampled. However, reads for the control sample, which was used for all comparisons, were not downsampled.

The first step to quantify A-to-I editing events is to count the actual bases occurring on RNA transcripts at positions that, according to the reference genome, are expected to harbor an adenine base. Thus, for transcripts oriented as the forward (reverse) reference strand, base counts must be collected at reference A-sites (T-sites). As noted above, the first (second) read in each pair of the stranded RNA-seq libraries has the same orientation as the first (second) cDNA strand—that is, the opposite (same) orientation as the transcript from which each cDNA molecule was synthesized. Also, Illumina sequencing technology fields both reads from opposite strands of the sequenced DNA molecule. Therefore, to handle transcripts oriented as the forward reference strand, base counts were collected at reference A-sites using the second (first) read in a pair, if that read was mapped to the forward (reverse) reference strand. Conversely, to handle transcripts oriented as the reverse reference strand, base counts were collected at reference T-sites using the first (second) read in a pair, if that read was mapped to the forward (reverse) reference strand.

The initial lists of base counts from all samples were then used to generate a final list of reference A- and T-sites in the final list were generated using ggplot2 (ref. 44). Note that the control sample, 2D histograms of the observed base proportions at all reference A-sites (T-sites) in the final list was 1,600,217 and 1,453,241 for human and mice samples, respectively. At each selected reference site in the final list, a pairwise comparison between the base counts for each treatment sample and those for the control sample was carried out using Fisher’s exact test, as implemented in the R function fisher.test, with a 2 × 2 contingency table containing the counts of (G+C) at reference A-sites (T-sites) in the first row, the counts of all other bases at those sites in the second row, the base counts for the control sample in the first column and the base counts for the compared treatment sample in the second column. The resulting P values were adjusted for multiple comparisons using the Benjamini–Hochberg method, as implemented in the R function p.adjust. The proportion of the number of G (C) bases relative to the number of all bases was also calculated at each A-site (T-site). Reference A-sites (T-sites) with a significant change in such base proportion for at least one comparison between a treatment sample and the control sample were selected by requiring an adjusted P value less than 0.01 and a fold change greater than 1.1 in either direction. To visually compare each treatment sample with the control sample, 2D histograms of the observed base proportions at all reference A- and T-sites in the final list were generated using ggplot2 (ref. 44). Note that the on-target editing efficiency values obtained in the RNA-seq are highly inflated due to a large number of reads coming from the cadRNAs mapping onto the target and, thus, were omitted from the 2D histograms. Long-read deep sequencing or Sanger sequencing was instead used to measure on-target editing.

Data availability
RNA-seq data for Fig. 2a and Extended Data Figs. 4 and 5c are accessible at the National Center for Biotechnology Information Gene Expression Omnibus under accession number GSE164956. Any other data can be obtained from the corresponding author upon reasonable request. Publicly available datasets used in this study are as follows: GRCm38, release 32, https://www.gencodegenes.org/mouse/release_32.html; GRCm38, release M27, https://www.gencodegenes.org/mouse/release_M27.html. Source data are provided with this paper.

Code availability
Code is available from the corresponding author upon reasonable request.

References
37. Garcia-Rivera, M. F. et al. Characterization of an immunodeficient mouse model of mucopolysaccharidosis type I suitable for preclinical testing of human stem cell and gene therapy. Brain Res. Bull. 74, 429–438 (2007).
38. Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
39. Frankish, A. et al. Gencode reference annotation for the human and mouse genomes. Nucleic Acids Res. 47, D766–D773 (2019).
40. Li, H. et al. The Sequence Alignment/Map format and SAMTools. Bioinformatics 25, 2078–2079 (2009).
41. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
42. Zhu, A., Ibrahim, J. G. & Love, M. I. Heavy-tailed prior distributions for sequence count data: removing the noise and preserving large differences. Bioinformatics 35, 2084–2092 (2019).
43. Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. 57, 289–300 (1995).
44. Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016).
45. Liu, Y., Wilson, T. J., McPhee, S. A. & Lilley, D. M. J. Crystal structure and mechanistic investigation of the twist ribozyme. Nat. Chem. Biol. 10, 739–744 (2014).
46. Felletti, M., Stief, J., Wurmthaler, L. A., Geiger, S. & Hartig, J. S. Twist ribozymes as highly versatile expression platforms for artificial riboswitches. Nat. Commun. 7, 12834 (2016).
47. Miao, H. et al. A long noncoding RNA distributed in both nucleus and cytoplasm operates in the PYCARD-regulated apoptosis by coordinating the epigenetic and translational regulation. PLoS Genet. 15, e1008144 (2019).

Acknowledgements
We thank G. Chen, L. Hodge, U. Parekh, R. Perales and other members of the Mali laboratory for discussions, advice and help with experiments. This work was generously supported by University of California, San Diego Institutional Funds and National Institutes of Health (NIH) grants (R01HG009285 (P.M.), R01CA222826 (P.M.), R01GM123313 (P.M.) and 1K01DK119687 (D.M.J.)). This publication includes data generated at the University of California, San Diego IGM Genomics Center using an Illumina NovaSeq 6000 that was purchased with funding from an NIH SIg grant (S10 OD026929). Schematics were created using BioRender.

Author contributions
D.K. and P.M. conceived the study and wrote the paper. D.K., P.M., J.Y., Y.K., A.S. and Y.S. performed experiments. D.M. quantified RNA editing activity from RNA-seq data.

Competing interests
D.K., J.Y. and P.M. have filed patents based on this work. P.M. is a scientific co-founder of Shape Therapeutics, Boundless Biosciences, Navega Therapeutics and Engine Biosciences. The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict of interest policies. Y.S. is an employee of Shape Therapeutics. D.K. is now an employee of Shape Therapeutics. The remaining authors declare no competing interests.

Additional information
Extended data is available for this paper at https://doi.org/10.1038/s41587-021-01171-4.
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41587-021-01171-4.
Correspondence and requests for materials should be addressed to Prashant Mali.

Peer review information Nature Biotechnology thanks Michael Jantsch and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at www.nature.com/reprints.
Extended Data Fig. 1 | Characterization of genetically encoded cadRNAs. (a) RNA editing efficiencies achieved 48 hours and 96 hours post transfection of circular.200.100 and ribozyme.mutant.200.100 plasmids. Ribozyme.mutant.200.100 was created by substituting two key residues in both twister ribozymes (P3 ribozyme: residue 15 G to U and residue 16 U to G; P1 ribozyme: residue 22 A to G and residue 26 C to U) of the construct circular.200.10045,46. Values represent mean ± SEM (n = 3; p = 0.0021, p = 0.0112; unpaired t-test, two-tailed). (b) Schematic representation of various products detected by inward and outward binding primers used for quantification. The outward binding primers selectively amplify the cadRNA. The inward binding primers amplify uncleaved and cleaved-unligated fractions in addition to cadRNA. Values represent mean ± SEM (n = 3). (c) Cells transfected with circular.200.100 and ribozyme.mutant.200.100 plasmids were treated with actinomycin D for 1, 6 and 16 hours starting at 24 hours post transfections. qPCRs were carried out using inward binding primers from panel (b) and expression levels were normalized to untreated samples. (d) Levels of circular.100.50 and linear.100.50 adRNA were measured in the nucleus and cytoplasm. GFP transfected cells were included as controls. U1 snRNA and GAPDH were used to normalize for the nuclear and cytoplasmic compartments respectively. Relative U1 snRNA and GAPDH levels seen in the nuclear vs cytoplasmic fractions were consistent with other published work47. Values represent mean ± SEM (n = 3). All experiments were carried out in HEK293FT cells.
Curbing bystander editing: RAB7A

Extended Data Fig. 2 | See next page for caption.
Extended Data Fig. 2 | Curbing bystander editing of the RAB7A transcript. Histograms of percent A-to-G editing within a 200 bp window around the target adenosine in the RAB7A transcript as quantified by Sanger sequencing. The target adenosine is located at position 0. The dsRNA stretch formed between the antisense and the target are shown below each histogram. Design 1 (cadRNA): Unmodified circular.200.100 antisense, in addition to the A-C mismatch at position 0, two mismatches are seen at positions +66 and +91 that were created to avoid a stretch of poly Us to allow for transcription from a U6 promoter. Design 2 (cadRNA.loops.interspersed.v1): Loops of size 8 bp created at position −5 and +30 relative to the target adenosine and additional 8 bp loops added at 15 bp intervals along the antisense strand. Design 3 (cadRNA.loops.interspersed.v2): As compared to v1, a G-mismatch was positioned opposite a highly edited A (at position +9), an additional 8 bp loop was added at position −81 and the loop at position +49 was changed to a 12 bp loop. Design 4 (cadRNA.loops.interspersed.v3): As compared to v1, the 8 bp loop at +30 was changed to a 12 bp loop starting at position +27, one additional 8 bp loop was added at position −81 and the loop at position +49 was changed to a 12 bp loop. Values represent mean % editing (n = 2). All experiments were carried out in HEK293FT cells.
Extended Data Fig. 3 | Characterization of IVT synthesized cadRNAs. qPCRs were carried out on cDNA synthesized from IVT-circular.200.100 adRNA and IVT-ribozyme.mutant.200.100 adRNA using primers binding to the ligation stem and ribozyme sequence. n.d.: not detected. Values represent mean ± SEM (n = 3).
Extended Data Fig. 4 | In vivo specificity of cadRNAs. 2D histograms comparing the transcriptome-wide A-to-G editing yields observed with an AAV delivered construct (y-axis) to the yields observed with the control AAV construct (x-axis). Each histogram represents the same set of reference sites, where read coverage was at least 10 and at least one putative editing event was detected in at least one sample. \( N_{\text{sig}} \) is the number of sites with significant changes in editing yield. Points corresponding to such sites are shown with red crosses. The on-target editing efficiency values obtained in the RNA seq are highly inflated due to a large number of reads coming from the cadRNAs mapping onto the target and thus have been omitted from the 2D histograms. The on-target editing values obtained via Sanger sequencing for the four samples analyzed by RNA seq were mCherry-M1: 0%, mCherry-M2: 0%, 2x.circular.200.100-M1: 42.94% and 2x.circular.200.100-M2: 41.32% respectively. M1 and M2 refer to injected mouse 1 and 2.
Extended Data Fig. 5 | Transcriptomic changes associated with in vivo cadRNA expression. (a) qPCRs were carried out on IFN-inducible genes involved in sensing of dsRNA 2 weeks and 8 weeks post AAV injections. Values represent mean ± SEM (n = 3; p-values for 2 week long experiment, 2x.circular.200.100 vs mCherry, for genes from left to right p = 0.0721, p = 0.0353, p = 0.8082, p = 0.0748, p = 0.0303; p-values for 8 week long experiment, 2x.circular.200.100 vs mCherry, for genes from left to right p = 0.7276, p = 0.6020, p = 0.3838, p = 0.3491, p = 0.2746; unpaired t-test, two-tailed). (b) qPCRs were carried out on ADAR variants 2 weeks and 8 weeks post AAV injections. Values represent mean ± SEM (n = 3; p-values for 2-week long experiment, 2x.circular.200.100 vs. mCherry, for ADAR variants from left to right p = 0.3165, p = 0.1885, p = 0.2815; p-values for 8 week long experiment, 2x.circular.200.100 vs. mCherry, for genes from left to right p = 0.8150, p = 0.1440, p = 0.9532; unpaired t-test, two-tailed). (c) Transcriptome-wide differentially expressed genes in the two groups: 2x.circular.200.100 vs. mCherry are highlighted in red.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- n/a Confirmed
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
  Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
  Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen’s d, Pearson’s r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

- Data collection: No software was used.
- Data analysis: GraphPad prism version 9.0.0 was used for plotting figures and computing associated p values
  RNA-seq data for HEK293T cells were analyzed using samtools version 1.10, R version 4.0.2, ggplot2 version 3.2.2, python version 3.8.6, perl version 5.30.0 and STAR version 2.7.3a
  RNA-seq data for mouse samples were analyzed using the above software versions except for the following differences: the version of STAR aligner was 2.7.7a; the version of samtools was 1.11; differential gene expression analysis was carried out using the Bioconductor package DESeq2 version 1.28.1
  CRISPResso2.1.0 was used for analysis of amplicon sequencing

For manuscripts utilizing custom algorithms or software that are not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

Data

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

RNA-seq data for Figure 2a and SI Figures 4, Sc is accessible via the NCBI GEO under accession GSE164956 and also is available from the corresponding author upon
Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

☒ Life sciences  ☐ Behavioural & social sciences  ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size  At least 2 independent samples per tested condition were evaluated. No statistical methods were used to predetermine sample size.

Data exclusions  No data was excluded.

Replication  2 or more independent biological replicates were evaluated for both in vitro studies in cultures cells and in vivo studies using mice. Findings were consistent in all replicates.

Randomization  Mice were randomly assigned into groups prior to injection. For cell culture experiments, transfection wells were randomly assigned.

Blinding  No blinding was carried out.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

| Materials & experimental systems | Methods |
|----------------------------------|---------|
| n/a  Involved in the study  n/a  Involved in the study | ☒ Antibodies  ☒ ChIP-seq |
| ☒ Eukaryotic cell lines  ☒ Palaeontology and archaeology | ☒ Flow cytometry |
| ☒ Human research participants  ☒ Dual use research of concern | ☒ MRI-based neuroimaging |

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)  HEK293FT (ThermoFisher), K562 [ATCC]

Authentication  STR, by vendor

Mycoplasma contamination  Tested by vendor, no mycoplasma contamination

Commonly misidentified lines (See [ICLC register])  HEK293FT cells were used for cell culture experiments and AAV production as per established procedures.
## Animals and other organisms

Policy information about [studies involving animals; ARRIVE guidelines](#) recommended for reporting animal research

| Category                  | Information                                                                 |
|---------------------------|-----------------------------------------------------------------------------|
| Laboratory animals        | Laboratory mice used in this study were obtained from the Jackson Laboratory. C57BL/6j mice and IDUA-W392X mice (B6.129S1-Iduatm1.1Kmke/J), male, 6-8 weeks of age. |
| Wild animals              | Study did not involve wild animals.                                          |
| Field-collected samples   | Study did not involve samples collected from the field.                     |
| Ethics oversight          | Institutional Animal Care and Use Committee of the University of California, San Diego. |

Note that full information on the approval of the study protocol must also be provided in the manuscript.